Sou Hu Cai Jing·2025-08-22 15:07Group 1 - The core viewpoint of the article highlights the financial performance and stock market activity of Haohai Biological Technology, indicating a decline in revenue and net profit for the first half of 2025 compared to the previous year [1] - On August 22, Haohai Biological's stock closed at 57.48 yuan, down 0.19% from the previous trading day, with a trading volume of 11,747 hands and a transaction amount of 0.67 billion yuan [1] - The company's total market capitalization is 133.69 billion yuan, with a price-to-earnings ratio of 31.67 times [1] Group 2 - According to the latest semi-annual report, the company achieved operating revenue of 1.304 billion yuan in the first half of 2025, a year-on-year decrease of 7.12%, and a net profit attributable to shareholders of 211 million yuan, down 10.29% year-on-year [1] - The second quarter showed a more pronounced decline, with revenue down 9.6% and net profit down 12.3% year-on-year [1] - By business segment, revenue from medical beauty and wound care products decreased by 16.8%, and revenue from ophthalmic products fell by 18.61%, while revenue from anti-adhesion and hemostatic products grew by 59.61% [1] Group 3 - The company announced a cash dividend of 4 yuan per 10 shares, with a total distribution amount expected to be 91.49 million yuan [1]